Royal Bank of Canada
CNTB

Royal Bank of Canada’s Connect Biopharma Holdings CNTB Stock Holding History

Royal Bank of Canada’s Portfolio CNTB Stock Details CNTB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$97K Buy
40,940
+540
+1% +$1.31K ﹤0.01% 5421
2026
Q1 		$106K Hold
40,400
– – ﹤0.01% 5087
2025
Q4 		$114K Buy
+40,400
New +$86.2K ﹤0.01% 5127
2025
Q3 		– Sell
-40,400
Closed -$40K – 7176
2025
Q2 		$40K Hold
40,400
– – ﹤0.01% 6008
2025
Q1 		$22K Sell
40,400
-40,000
-50% -$37.1K ﹤0.01% 5876
2024
Q4 		$111K Buy
80,400
+49,800
+163% +$57.3K ﹤0.01% 5271
2024
Q3 		$44K Buy
30,600
+17,900
+141% +$21.8K ﹤0.01% 5759
2024
Q2 		$19K Buy
+12,700
New +$20.9K ﹤0.01% 6093
2024
Q1 		– Sell
-449
Closed -$1K – 7073
2023
Q4 		$1K Buy
449
+194
+76% +$230 ﹤0.01% 6902
2023
Q3 		$0 Buy
255
+220
+629% +$200 ﹤0.01% 7139
2023
Q2 		$0 Sell
35
-6
-15% -$7 ﹤0.01% 7304
2023
Q1 		$0 Sell
41
-39
-49% -$43 ﹤0.01% 7118
2022
Q4 		$0 Sell
80
-72
-47% -$59 ﹤0.01% 7282
2022
Q3 		$0 Buy
+152
New +$183 ﹤0.01% 7489

Other funds holding CNTB

IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
RB
Richmond Brothers Jackson, Michigan $192M AUM 23.02% 1-Year Est. Return
DMKJ
David M. Knott Jr $189M AUM 67.72% 1-Year Est. Return

Royal Bank of Canada's CNTB Position: Q2 2026 in Review

Royal Bank of Canada increased its Connect Biopharma Holdings (CNTB) stake by 1.3% in Q2 2026, buying an estimated $1.31K and bringing the position to 40,940 shares worth $97K. The position accounts for ﹤0.01% of the portfolio, ranked #5421.

Royal Bank of Canada first reported a position in CNTB in Q3 2022 and has held it in 14 quarters since. The position peaked at $114K in Q4 2025. 56 funds tracked by Wall St. Rank hold CNTB as of Q2 2026.

  • Royal Bank of Canada held 40,940 shares of Connect Biopharma Holdings worth $97K as of Q2 2026.
  • Royal Bank of Canada bought 540 Connect Biopharma Holdings shares in Q2 2026, an estimated $1.31K.
  • Connect Biopharma Holdings made up ﹤0.01% of Royal Bank of Canada's portfolio in Q2 2026, its #5421 holding.
  • Royal Bank of Canada first reported a position in Connect Biopharma Holdings in Q3 2022 and has held it in 14 quarters since.
  • Royal Bank of Canada's Connect Biopharma Holdings position peaked at $114K in Q4 2025.
  • 56 funds tracked by Wall St. Rank held Connect Biopharma Holdings as of Q2 2026.

Based on Royal Bank of Canada's 13F filing for Q2 2026, filed 14 Aug 2026.